Table 2.

Prognostic factors for overall survival in the three groups.

Variables	Univariate HR (95% CI)	P	Multivariate HR (95% CI)	P
Sex (male vs. female)	1.587 (0.743–3.390)	0.233
Age (≤60 vs. >60 years)	0.275 (0.140–0.541)	<0.001	0.280 (0.142–0.555)	<0.001
Primary sites (stomach vs. others)	0.984 (0.489–1.983)	0.965
Metastatic phase (metachronous vs. synchronous)	0.684 (0.352–1.328)	0.262
Number of metastases (≤3 vs. >3)	0.431 (0.202–0.920)	0.030	0.509 (0.229–1.131)	0.098
Largest diameter of metastases (≤3 vs. >3 cm)	1.263 (0.649–2.458)	0.492
Extrahepatic metastases (no vs. yes)	0.661 (0.332–1.319)	0.240
Therapy
IM alone	Reference	–	Reference	–
IM+HR	0.264 (0.100–0.696)	0.007	0.361 (0.132–0.985)	0.047
IM+RFA/TACE	0.887 (0.362–2.173)	0.794	1.016 (0.404–2.551)	0.974

HR, hazard ratio.

HR, hepatic resection; IM, imatinib; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.